Marek Health Review 2026: Lab Testing, TRT & Peptides

The androgen picture is complete rather than partial: total testosterone, free testosterone, SHBG, albumin, LH, FSH, sensitive estradiol, DHT, prolactin and IGF-1. That combination is what lets a clinician distinguish primary from secondary hypogonadism, work out whether a low free testosterone is an SHBG problem rather than a production problem, and decide whether an aromatase inhibitor is ever justified — which, on most protocols, it is not.

Around that sits a full metabolic and cardiovascular workup: lipids with ApoB, hs-CRP, fasting insulin, HbA1c, complete blood count with hematocrit, comprehensive metabolic panel, thyroid with free T3 and free T4, PSA, and iron studies. The Complete panel extends further into nutrient status and additional cardiovascular markers.

Hematocrit and PSA being standard rather than optional is a small detail that says a lot. Erythrocytosis is the complication most likely to force a change to a testosterone protocol, and services that only sell you a testosterone number are not monitoring the thing most likely to hurt you.

Every panel comes with a written report and a video review. The written reports are unusually long and go marker by marker, with context on what the number means in the presence of the others rather than in isolation. The video review is where the value concentrates — the coaches will tell you when a protocol looks reckless, when a symptom is not explained by your labs, and when the honest answer is that nothing needs changing.

Coaches are not physicians. They interpret and advise; prescribing runs through affiliated clinicians. In practice this works well because the interpretation is the part most services do badly, but it does mean the relationship spans two parties rather than one.

Marek interprets your labs and also sells the treatment. That is the same structure as every optimization clinic, and it does not make the advice wrong — but it does mean a recommendation to add a peptide, a supplement stack or an ancillary medication deserves more scrutiny than the same recommendation from someone with nothing to sell.

The practical defence is simple: ask what marker would tell you the addition is working, and what you would do if it does not move. If there is no such marker, the recommendation is speculative regardless of who made it.

Against Hone Health, Marek is several times the price and several times the depth. Hone gets you from a low number to a prescription cheaply; Marek gets you a protocol that accounts for SHBG, estradiol management, hematocrit trajectory and fertility. If you are going to be on hormone therapy for a decade, that difference compounds.

Against Function Health, the comparison is category error. Function screens broadly and cannot treat. Marek goes deep on one system and can. Some people reasonably run both — Function annually for the whole-body picture, Marek for the hormone protocol.

Beyond the two fixed panels, Marek runs a lab builder — an à la carte ordering tool where you assemble your own draw from individual markers and single-marker add-ons rather than buying a bundle. It is the right route when you already have a baseline and only need a follow-up: a hematocrit and estradiol recheck eight weeks into a dose change costs a fraction of a full Comprehensive panel.

Draws run through national reference-lab patient service centers, so availability is broad and you are not tied to a particular metro. Results land in the Marek portal, which keeps a longitudinal view of every marker across draws — that trend view is the part that makes repeat testing useful rather than just repetitive.

As a diagnostic tool, treat it the way a clinician would: order markers you have a decision rule for. Adding twenty markers you will not act on produces noise and false alarms, and Marek's own coaches will generally say the same.

Marek is one of the clinics most associated with peptide protocols, and the honest picture in 2026 is more restricted than the internet suggests. BPC-157 sits on the FDA's list of substances that cannot be used in compounded preparations, so any legitimate US clinic — Marek included — cannot dispense it as a prescription compound. Availability of specific peptides changes with FDA guidance, and a clinic that promises BPC-157 without qualification is a red flag rather than a feature.

What clinicians in this space do prescribe, where clinically justified, are the growth-hormone secretagogues and metabolic peptides with clearer regulatory standing, plus the GLP-1 class for metabolic indications. Our position is unchanged: peptides are educational content here, not a recommendation, and the evidence tier varies enormously between compounds.

If peptides are your main reason for considering Marek, ask directly what they can dispense today, under what indication, and what marker they will use to judge whether it is working. A clinic that answers all three clearly is worth the money; one that does not is selling hope.